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Resumo 
 
Introdução: Em Portugal, todos os doentes com PKU são submetidos a um 
teste de sobrecarga (TS) para avaliar a sua resposta à BH4. Antes do TS, a 
ingestão de fenilalanina (Fen)/proteína natural (PN) é aumentada para atingir 
valores de [Fen] no sangue > 480 μmol/L. Pretende-se verificar o impacto do 
aumento de Fen/PN no controlo metabólico pós-TS, particularmente nos não-
respondedores. 
Metodologia: 58 doentes PKU (4-34 anos; 19.6±8.2 anos; 50% mulheres; 
48.3% PKU clássica, 51.7% PKU moderada) que completaram o TS em 2015 
foram estudados em 4 períodos de estudo (PE). No PE1 (2010-2013) o 
tratamento foi exclusivamente dietético. No PE2 (2014) iniciou-se o aumento da 
ingestão de Fen/PN. Os TSs foram concluídos no PE3 (2015). No PE4 (2016) 
coexistiram doentes tratados exclusivamente com dieta (N=49) e doentes a 
tomar BH4 (N=9). Foram recolhidos dados de antropometria, ingestão proteica 
e controlo metabólico. 
Resultados: A percentagem de doseamentos de Fen dentro do intervalo 
recomendado foi maior no PE1 vs. PE4 (64 [28-85] vs. 45 [0-66]; p<0,001). No 
PE1, 39,7% dos doentes tinham bom controlo metabólico, enquanto no PE4 
este valor foi de apenas 22,4%. A mediana das diferenças da percentagem de 
valores dentro do intervalo recomendado entre o PE4 e o PE1 não foi 
estatisticamente diferente quando comparados os doentes tratados com BH4 
vs. com dieta: -1 [-46;22] vs. -17 [-33;0]; p=0,408.  
Conclusão: Apesar do controlo metabólico piorar com a idade, os resultados 
sugerem que um aumento temporário da ingestão de Fen/PN poderá afetar 
negativamente o controlo metabólico. São necessários mais estudos acerca do 
efeito do TS a longo prazo, revendo a duração e as estratégias utilizadas na 
preparação do mesmo.  
 
Palavras Chave: Fenilcetonúria; Teste de sobrecarga BH4; Controlo 
metabólico 
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Abstract 
 
Background: In Portugal, for PKU, all potential BH4 responders are identified 
using a loading test (LT). Phenylalanine (Phe)/natural protein (NP) intake is 
increased to elevate blood [Phe] > 480 μmol/L prior to LT. We aimed to verify 
the impact of Phe/NP titration on metabolic control post-LT in PKU patients, 
particularly in non-responders. 
Patients and Methods: 58 PKU patients (4-34 y; 19.6 ± 8.2 y; 50% females; 
48.3% classical PKU, 51.7% mild PKU) that completed LT in 2015 were studied 
in 4 different study periods (SP). At SP1 (2010-2013) patients were exclusively 
diet treated. Phe/NP titration was started during SP2 (2014). LTs were 
concluded in SP3 (2015). In SP4 (2016) patients were either exclusively diet 
treated (N=49) or BH4 treated (N=9). Anthropometry, protein ingestion and 
metabolic control data were collected and analyzed. 
Results: Blood Phe measurements within target range (median %) was higher 
in SP1 vs. SP4 (64 [28-85] vs. 45 [0-66]; p<0,001). In SP1 there were 39.7% of 
patients under good metabolic control compared to 22.4% in SP4. The median 
of differences of blood Phe measurements within target range between SP4 
and SP1 was not statistically different in BH4 treated vs. diet treated patients: -1 
[-46;22] vs. -17 [-33;0]; p=0,408.  
Conclusion: Although worsening blood [Phe] control may occur over time, our 
results suggest that transient Phe/NP titration may adversely affect long term 
blood [Phe] control. Studies examining the long-term effect of LT, including a 
review of length and strategy of preparation for LT are necessary. 
 
Keywords: Phenylketonuria; BH4 loading test; Metabolic control
iii 
 
 
 
Índex 
 
Resumo ............................................................................................................... i 
Abstract ............................................................................................................... ii 
1. Introduction ..................................................................................................... 1 
2. Methods.......................................................................................................... 2 
2.1 Participants ................................................................................................... 2 
2.2 Study Design ................................................................................................ 3 
2.3 Data Collection ............................................................................................. 4 
2.3.1 Anthropometry ........................................................................................... 4 
2.3.2 Nutritional Intake ....................................................................................... 4 
2.3.3 Metabolic Control ...................................................................................... 4 
2.4 Ethical Statement ......................................................................................... 5 
2.5 Statistical Analysis ........................................................................................ 5 
3. Results ........................................................................................................... 5 
4. Discussion ...................................................................................................... 9 
5. Conclusion .................................................................................................... 12 
Acknowledgements .......................................................................................... 12 
References ....................................................................................................... 13 
  
 
 
 
 
1 
 
 
 
1. Introduction 
Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine 
(Phe) metabolism, affecting 1:10000 newborn babies in Europe, caused by a 
phenylalanine hydroxylase (PAH) enzyme deficiency (1). Therefore, the conversion 
of Phe (either from diet or endogenous catabolism) into tyrosine (Tyr) is 
compromised, resulting in increased blood [Phe]. Phe is a large neutral amino acid 
able to cross the blood brain barrier using L-amino acid transporter 1 (LAT1). High 
brain [Phe] leads to neuropsychological impairment through different mechanisms: 
(1) decrease in myelin formation in brain white matter; (2) inhibition in brain 
availability of Tyr (dopamine and norepinephrine precursor), tryptophan (serotonin 
precursor) and other large neutral amino acids except Phe, compromising protein 
and neurotransmitter synthesis; (3) inhibition of key enzymes involved in 
neurotransmitter synthesis and intermediary metabolism (2). Thus, neonatal 
screening is essential to early identify PKU patients in order to promptly implement 
treatment, preventing future intellectual disability (1, 2). Diet is the core of PKU 
treatment, involving a severe restriction of Phe and natural protein (NP) intake, 
replacement of non-Phe protein with a protein substitute (PS) and low-protein 
foods (including special low-protein foods) to satisfy energy needs (3, 4). In 
Portugal, PS are available as either Phe-free amino-acid mixtures, 
glycomacropeptide-based PS and large neutral amino acids (5).  
Maintaining life-long adherence to this restricted diet is challenging, especially in 
older children (6). It is well established there is a deterioration of metabolic control 
over time, particularly in late adolescence and adulthood (6-9).  
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More recently, the administration of pharmacological doses of tetrahydrobiopterin 
(BH4), the PAH co-factor, available as a commercial formula of sapropterin 
dihydrochloride (Kuvan®), may help improve metabolic control, improving dietary 
Phe tolerance in a sub-set of patients with mild or moderate PKU (10-12). BH4 
responsiveness can be established either by genotype or with a loading test (LT) 
(1). The PKU European guidelines suggest that in patients without two known 
disease null mutations or two known BH4 responsive mutations, a LT should be 
performed (1). A 48h BH4 LT protocol has been used in Europe, analysing blood 
[Phe] before and after a single daily dose of sapropterin (20 mg/Kg/day) on two 
consecutive days (13, 14). 
However, different methodologies in different countries are used to evaluate BH4 
responsiveness (13, 14). In Portugal, the Portuguese Society for Metabolic Disorders 
(SPDM) policy is to identify all potential BH4 responders using a LT. Phe and NP 
intakes are increased to elevate blood [Phe] > 480 μmol/L prior to LT and 
sometimes this procedure is challenging both for patients and professionals (15). 
There are no studies describing the impact of a short-term increase in Phe and NP 
intake on long term blood [Phe], particularly in non-responders.  
In a longitudinal, retrospective study, we aimed to examine the impact of Phe and 
NP titration on metabolic control post-LT in PKU patients. 
 
2. Methods 
2.1 Participants 
In 2015, 66 patients with PKU completed a LT from the Reference Center of 
Inherited Metabolic Diseases of Centro Hospitalar do Porto. Eight patients were 
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excluded from the study: 5 were late diagnosed (late treated patients with 
inconsistent dietary compliance), 2 had insufficient clinical data and dietary 
records and 1 had Down Syndrome with severe neurological impairment affecting 
dietary management (16). The final sample included 58 (N=58) early treated 
patients (4-34 years; 19.6 ± 8.2 years; 50% females). Disease severity was 
classified according to the neonatal blood [Phe], as stated at the Portuguese 
Consensus (17): hyperphenylalaninemia (blood [Phe] < 6 mg/dL), mild PKU (blood 
[Phe] ≥ 6 mg/dL and ≤ 20 mg/dL) and classical PKU (blood [Phe] > 20 mg/dL). 
There was 30 mild PKU patients (51.7%) and 28 classical PKU patients (48.3%). 
The blood [Phe] target range was ≤ 6 or ≤ 8 mg/dL with patients aged < 12 or ≥ 12 
years, respectively (17). 
The final sample of patients was studied in 4 different study periods (SP). During 
the study period SP1 (2010-2013) all patients were on a low Phe diet. In SP2 
(2014), the NP prescription was increased to define maximum Phe tolerance to 
establish a blood [Phe] > 480 μmol/L, according to SPDM protocol. In the SP3 
(2015), the preparation for LT was continued and patients were gradually enrolled, 
while some potential BH4 responders had already started sapropterin treatment. In 
the SP4 (2016), patients were either exclusively diet treated (N=49) or under BH4 
treatment (N=9). 
2.2 Study Design 
This is a longitudinal retrospective study, and data was collected from 2010 to 
2016. Gender, birthdate, neonatal blood [Phe], disease severity, genotype, date of 
LT and sapropterin responsiveness were collected from electronic clinical records 
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of patients. Participants were identified by a code, preventing patient’s 
identification. Data on anthropometry and nutritional intake were collected from 
clinical records from the final nutritional appointment of each SP. All blood Phe 
measurements done in SP1, SP2, SP3 and SP4, for each patient, were collected 
from the patient database.   
2.3 Data Collection 
2.3.1 Anthropometry 
Weight and height were measured when patients were in light clothing only, 
without shoes and accessories. Seca® mechanic scale (measuring scale = 1 Kg) 
and a stadiometer (measuring scale = 1 mm) were used. Body mass index (BMI) 
was calculated as weight (Kg) / height2 (m) and classified by World Health 
Organization criteria (18). Anthro® and Anthro Plus® software were used to calculate 
BMI z-scores for patients aged between 0-5 years and 5-19 years, respectively. 
For patients aged 0-5 years, overweight was defined when BMI z-score was > 2 
standard-deviations (19, 20). In patients aged between 5-19 years, overweight was 
considered when BMI z-score was > 1 standard-deviation (20, 21). 
2.3.2 Nutritional Intake 
Dietary assessment was performed by a 24-hour recall. NP (g/Kg/day), protein 
equivalent (PE) from PS (g/Kg/day) and total protein (TP) (g/Kg/day) intakes were 
calculated. 
2.3.3 Metabolic Control 
Blood [Phe] was measured from blood-spots by tandem mass spectrometry. All 
patient blood Phe measurements in each of the 4 SP were calculated for median, 
mean and standard-deviation of blood [Phe]. Furthermore, for each period and 
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each patient, percentage of blood Phe measurements within target range was 
calculated. Whenever patients reached 12 years old (N=14), the upper target 
range was adjusted so results were correctly interpreted (17). 
2.4 Ethical Statement 
This study and its data collection were under the ethical approval consented by the 
Ethics Committee of Centro Hospitalar do Porto, on the18th of May 2015, to the 
investigation project TNSPKU (Trends in Nutritional Status of patients with 
phenylketonuria), with the reference 2015.101 (092-DEFI/087-CES). Written 
informed consent was obtained from each patient or caregiver. 
2.5 Statistical Analysis 
IBM SPSS Statistics 24 for Windows was used for statistical analyses. 
Kolmogorov-Smirnov test was done to evaluate normal distribution of variables. 
Categorical variables were presented as absolute values or percentage, and 
continuous variables were presented as mean ± SDs or as medians [P25-P75], 
according to its distribution. Wilcoxon test and Mann-Whitney test were used to 
identify differences when non-normal distribution was found. The level of 
significance considered was p<0.05. 
 
3. Results 
Patient’s characteristics are described in Table 1. No overweight or obesity was 
found in patients < 5 y, whereas the prevalence increased in adults (Table 2). 
6 
None of the patients who were overweight or obese in 2013 became normal 
weight in 2016 (data not shown). 
Table 1. Gender, age and disease severity of patients studied. 
Sample Size N=58 
Gender 
Female: N=29 (50%) 
Male: N=29 (50%) 
Age (at LT a - 2015) 
19.6 ± 8.2 y (Min=4 y; Max=34 y) 
<19 y: N=24 (41.4%) 
≥19 y: N=34 (58.6%) 
Disease Severity 
Mild PKU: N=30 (51.7%) 
Classical PKU: N=28 (48.3%) 
 a LT – BH4 loading test 
Table 2. Anthropometric data of patients studied in SP1 vs. SP4. 
Anthropometry 
SP1 SP4 
[0-5] y 
 
N = 3 
]5-19] y 
 
N = 28 
>19 y 
 
N = 27 
[0-5] y 
 
N=0 
]5-19] y 
 
N = 24 
>19 y 
 
N = 34 
BMI 
 
BMI z-score 
- 
 
0.30±0.6 
- 
 
0.23±1.1 
22.8±4.6 
 
- 
- 
 
- 
- 
 
0.17±1.2 
23.9±4.7 
 
- 
Overweight / 
Obesity 
N = 0 N = 9 N = 6 - N = 9 N = 11 
Overweight / 
Obesity 
Prevalence (%) 
25.9% 34.5% 
 
During the 4 study periods, NP intake (g/kg/day) remained similar, with a trend to a 
lower PE intake (g/kg/day), which is reflected in a lower TP intake in ST4 (Table 
3).  
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Table 3. Protein intake in patients. 
 
Median blood [Phe] was lower in SP1 than in SP4 (6.80 [4.70-10.30] vs. 7.91 
[6.53-11.11]; p<0,001) (Table 4). The percentage of blood [Phe] within target 
range was higher in SP1 compared with SP4 (64% [28-85] vs. 45% [0-66]; 
p<0,001) (Table 4). In SP4, 16 patients (27.6%) did not have any blood Phe 
measurement within the target range compared with 6 (10.3%) patients in SP1. 
Changes in blood [Phe] control throughout the study are illustrated in Figure 1.  
Table 4. Metabolic control of patients during the 4 periods of the study. 
a Phe - Phenylalanine;  
P25 - 25th percentile;  
P75 - 75th percentile. 
 
 
Protein intake 
 
SP1 SP2 SP3 SP4 
Natural protein intake 
(g/Kg/day) 
0.58 ± 0.3 0.53 ± 0.3 0.50 ± 0.3 0.55 ± 0.3 
Protein equivalent intake 
(g/Kg/day) 
1.12 ± 0.4 0.95 ± 0.3 0.92 ± 0.3 0.84 ± 0.30 
Total protein intake 
(g/Kg/day) 
1.72 ± 0.4 1.49 ± 0.3 1.46 ± 0.4 1.41 ± 0.3 
 
Metabolic Control 
 
SP1 SP 2 SP 3 SP 4 
Median [Phe] a (mg/dL) 
6.80 
P25 = 4.70 
P75 = 10.30 
7.98 
P25 = 5.85 
P75 = 10.58 
8.20 
P25 = 6.80 
P75 = 10.25 
7.91 
P25 = 6.53 
P75 = 11.11 
Phe measurements 
within target range (%) 
64 
P25 = 28 
P75 = 85 
47 
P25 = 7 
P75 = 76 
38 
P25 = 18 
P75 = 62 
45 
P25 = 0 
P75 = 66 
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Figure 1. Evolution of metabolic control of the 58 patients studied. 
 
In SP1 there were almost twice as many patients in good metabolic control 
(39.7%) compared to SP4 (22.4%) (Table 5). Table 6 presents data on 
percentages of blood Phe measurements within target range at SP1 and SP4, for 
patients on sapropterin treatment and diet treatment only. In these sub-groups, the 
median of differences between SP1 and SP4 was -1 [-46;22] and -17 [-33;0], not 
reaching statistical significance (p=0,408) (Table 6). 
Table 5. Metabolic Control Quality. 
Metabolic Control 
(% of patients per 
class) 
SP1 SP4 
<75%  
“Bad control” 
≥75% 
“Good 
control” 
<75% 
“Bad control” 
≥75% 
“Good 
control” 
60.3 39.7 77.6 22.4 
Phe measurements within target range ≥75% - “Good control” 
Phe measurements within target range <75% - “Bad control” 
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Table 6. Metabolic Control. 
Metabolic Control (% of Phe measurements within target range) 
On BH4 Treatment in 2016 (N=9)a Without BH4 Treatment in 2016 (N=49) 
SP1 SP4 SP1 SP4 
90 
P25 = 65 
P75 = 97 
83 
P25 = 48 
P75 = 91 
58 
P25 = 21 
P75 = 80 
41 
P25 = 0 
P75 = 57 
Median of differences = -1 [-46;22] Median of differences = -17 [-33;0] 
a Some patients have responded to LT but only initiated medication during/after 
2016 or stopped medication (N=6). This table only represents patients on 
medication in 2016. 
 
4. Discussion 
The most important finding of this study is the suggestion that patients who 
received a sapropterin LT, with a temporary increase in NP pre-test, had a worse 
Phe control one year post test, which later saw a trend towards a slight 
improvement. Both the percentage of blood Phe measurements within target 
range at SP1 compared with SP4, and the contrast between percentage of 
patients under good metabolic in SP1 and SP4, support our conclusions.  
We recognise that many factors may have led to deterioration in blood [Phe] 
control in addition to sapropterin LT. Diet treatment for PKU patients is extremely 
restrictive and PS have a strong taste and odor, so adherence is challenging (7, 8). 
After the age of 10 years, it is well recognised that dietary adherence is 
challenging, associated with dietary management transition to self-care, increasing 
10 
socialisation and hunger (6, 7). Accordingly, a progressive deterioration in metabolic 
control with age, particularly in adolescents and younger adults is established (1, 6, 
8). During adolescence and adulthood, there is a relaxation of the diet: pleasure of 
food becomes more important, there are time constraints and stress associated 
with food preparation, and sometimes it is difficult to comprise restrictions of these 
patients with their lifestyle (9). 
Considering that during the 4 SP the cohort of patients increased in age, it seemed 
more appropriate to analyse the percentage of blood Phe levels within target 
range rather than median blood levels, as  target ranges are already age-adjusted 
(17).  
The choice of foods for increasing NP intake for the Phe titration may have 
affected the results. Increasing Phe intake using milk sources together with PS 
was not practical in older patients as previously recommended (15). In many adult 
PKU patients a liquid PS was prescribed, and it was not possible to add other NP 
sources to it. In addition, the known milder spectrum of the disease usually found 
in Portugal also influenced the practical strategies used to increase diet Phe intake 
(22). It was verified high Phe tolerance in many patients, so regular foods with a 
high protein content was given for the temporary increase in Phe intake, e.g., 
regular bread and pasta, milk, cheese and yogurt.  
Analysing the SP4 in particular, it seems that the degree of metabolic control 
deterioration was greater in the group without BH4 treatment compared with BH4 
treated patients, suggesting a negative effect of the temporary exposure to the 
additional Phe prior LT. While some patients were afraid to introduce high protein 
foods into their daily routine, others enjoyed their taste (23). We cannot rule out the 
psychological consequences on feeding behavior of giving additional NP and then 
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withdrawing it again in non-responders. The difficulty and disappointment in 
returning to their previous restricted diet should not be underestimated in non-
responders (15).   
In the process of Phe titration, PS prescription was maintained during preparation 
for LT. However, considering the weight variations throughout the study (Table 2), 
stabilizing PS prescription resulted in a lower TP intake interpreted in terms of 
g/kg. Also the observed weight changes may have justified an increase PE 
prescription, in order to theoretically prevent any negative effect in terms of 
metabolic control. 
Our study has several limitations. First, there was no opportunity to identify the 
exact starting date of the LT preparation phase, because some patients already 
had blood [Phe] high enough to perform the test with no need to modify their diet. 
In practice, if the precise length of NP titration process was possible to be 
determined, a clearer impact could be seen. For the same reason, we were unable 
to describe the precise Phe/NP increase for each patient, by how much and by 
which foods, during preparation for LT. Moreover, this was a retrospective and 
non-controlled study that analyzed metabolic control in a group of PKU patients 
under follow-up and proposed for BH4-LT. Also, it was not possible to have a 
control group. Although we have used the percentage of blood Phe measurements 
within target range, which is already age-adjusted, our group had a wide age 
range which may have influenced compliance and metabolic control. Finally, in 
SP4, the comparison between BH4 treated and diet treated patients should be 
analyzed carefully due to the small group of patients under drug treatment. 
However, this is the first study evaluating the effect of the LT procedures on 
12 
metabolic control, involving just patients from one reference treatment centre and 
collecting data only from the year following the LT.  
 
5. Conclusion 
In conclusion, although a deterioration of blood [Phe] control may occur over time, 
our results suggest that a transient Phe and NP titration may further adversely 
affect metabolic control, particularly in non-responders. Even though the use of 
sapropterin has been described as a good co-adjuvant for BH4-responders, there 
are many different protocols for assessing BH4 responsiveness. A multicentre and 
controlled study would be helpful to examine the long-term effect of different 
methodologies on metabolic control, including a review of length and strategy of 
preparation for the LT and the assessment of its relevance. 
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